Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).

Under the terms of the agreement, Novartis has agreed to pay Voyager $100 million of up-front consideration, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to an additional $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.

Sarah Hogan, Elese Hanson and Drew Fosque advised Voyager on the collaboration and license agreement. Brian Johnson, Avery Reaves, Sarah Matchett and Frank Wang advised on the equity investment, related arrangements and general corporate matters.